A new wound healing agent--sphingosylphosphorylcholine

Area of Science:

• Biochemistry
• Dermatology
• Regenerative Medicine

Background:

• Sphingosylphosphorylcholine (SPC), also known as lysosphingomyelin, is a cell growth-promoting agent.
• Impaired wound healing is a significant clinical challenge, particularly in diabetic individuals.

Purpose of the Study:

• To evaluate the efficacy of SPC in promoting the healing of full-thickness excision and incision wounds in diabetic mice.
• To investigate the effects of SPC on cell proliferation and tissue regeneration in wound healing models.

Main Methods:

• Assessment of wound closure rate, skin strength, and tissue histology in diabetic (db/db) and non-diabetic (db/+) mice.
• Measurement of cell proliferation in vivo (bromo-deoxyuridine incorporation) and in vitro ([3H] thymidine incorporation).
• Histological analysis of mitotic cell counts, scar area, and tissue normalization.

Main Results:

• SPC significantly increased the rate of wound closure (p < 0.02) at an optimal concentration of 2-3 microM.
• SPC stimulated DNA synthesis in key wound-healing cells, including microvascular endothelial cells, and promoted proliferation of keratinocytes, fibroblasts, and other dermal cells in vivo.
• Histological analysis revealed a 3-fold increase in mitotic cells, reduced scar area, and more normalized tissue morphology at wound sites.

Conclusions:

• SPC effectively accelerates dermal wound healing in animal models, including those with impaired healing.
• The compound promotes re-epithelialization and granulation tissue formation without negatively impacting skin strength.
• These findings support SPC as a promising candidate for clinical applications in wound management.